PT1005870E - Aplicação terapêutica de anticorpos quiméricos contra antigénio de diferenciação restrita de linfócitos b humanos, para o tratamento do linfoma de células b - Google Patents

Aplicação terapêutica de anticorpos quiméricos contra antigénio de diferenciação restrita de linfócitos b humanos, para o tratamento do linfoma de células b Download PDF

Info

Publication number: PT1005870E
Authority: PT; Portugal
Prior art keywords: human; treatment; cell lymphoma; chimeric antibodies; therapeutic application
Prior art date: 1992-11-13

Application number

PT99123967T

Other languages

English (en)

Inventor

William H Rastetter

Mitchell E Reff

Nabil Hanna

Darrell R Anderson

John E Leonard

Roland A Newman

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-13

Filing date

1993-11-12

Publication date

2009-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25526490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1005870(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-11-12 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2009-04-28 Publication of PT1005870E publication Critical patent/PT1005870E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PT99123967T 1992-11-13 1993-11-12 Aplicação terapêutica de anticorpos quiméricos contra antigénio de diferenciação restrita de linfócitos b humanos, para o tratamento do linfoma de células b PT1005870E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97889192A	1992-11-13	1992-11-13
US08/149,099 US5736137A (en)	1992-11-13	1993-11-03	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Publications (1)

Publication Number	Publication Date
PT1005870E true PT1005870E (pt)	2009-04-28

Family

ID=25526490

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT99123967T PT1005870E (pt)	1992-11-13	1993-11-12	Aplicação terapêutica de anticorpos quiméricos contra antigénio de diferenciação restrita de linfócitos b humanos, para o tratamento do linfoma de células b
PT08013898T PT2000149E (pt)	1992-11-13	1993-11-12	Anticorpo quimérico anti-cd20

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT08013898T PT2000149E (pt)	1992-11-13	1993-11-12	Anticorpo quimérico anti-cd20

Country Status (24)

Country	Link
US (2)	US5736137A (pt)
EP (1)	EP2000149B1 (pt)
KR (1)	KR100365632B1 (pt)
CN (5)	CN1607006B (pt)
AT (2)	ATE421335T1 (pt)
BR (1)	BR1100622A (pt)
CA (1)	CA2626445A1 (pt)
DE (3)	DE69334285D1 (pt)
DK (2)	DK1005870T3 (pt)
ES (2)	ES2326144T3 (pt)
FR (1)	FR04C0018I2 (pt)
GE (3)	GEP20074162B (pt)
HK (3)	HK1109634A1 (pt)
HU (1)	HU219264B (pt)
IL (1)	IL107591A (pt)
LU (1)	LU91620I2 (pt)
MY (1)	MY111196A (pt)
NL (1)	NL300424I1 (pt)
PL (1)	PL175557B1 (pt)
PT (2)	PT1005870E (pt)
SG (1)	SG45294A1 (pt)
TW (1)	TW376320B (pt)
UA (1)	UA27946C2 (pt)
ZA (1)	ZA938466B (pt)

Families Citing this family (723)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) *	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
NZ258392A (en) *	1992-11-13	1997-09-22	Idec Pharma Corp	Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5885574A (en) *	1994-07-26	1999-03-23	Amgen Inc.	Antibodies which activate an erythropoietin receptor
US8771694B2 (en) *	1994-08-12	2014-07-08	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
ATE306930T1 (de) *	1994-08-12	2005-11-15	Immunomedics Inc	Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US20030180290A1 (en) *	1995-06-07	2003-09-25	Idec Pharmaceuticals Corporation	Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6373497B1 (en) *	1999-05-14	2002-04-16	Zight Corporation	Time sequential lookup table arrangement for a display
US7033589B1 (en) *	1997-02-20	2006-04-25	Biogen Idec Ma Inc.	γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) *	1997-02-20	2005-05-17	Biogen Idec Ma Inc.	Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6991790B1 (en) *	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
US6699672B1 (en)	1997-09-02	2004-03-02	Insight Biopharmaceuticals Ltd.	Heparanase specific molecular probes and their use research and medical applications
US20040213789A1 (en) *	1997-09-02	2004-10-28	Oron Yacoby-Zeevi	Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20020088019A1 (en) *	1997-09-02	2002-07-04	Oron Yacoby-Zeevi	Methods of and pharmaceutical compositions for improving implantation of embryos
US20010006630A1 (en) *	1997-09-02	2001-07-05	Oron Yacoby-Zeevi	Introducing a biological material into a patient
US6177545B1 (en) *	1997-09-02	2001-01-23	Insight Strategy & Marketing Ltd.	Heparanase specific molecular probes and their use in research and medical applications
US20030161823A1 (en) *	1998-08-31	2003-08-28	Neta Ilan	Therapeutic and cosmetic uses of heparanases
US6562950B2 (en) *	1997-09-02	2003-05-13	Insight Strategy & Marketing Ltd.	Heparanase activity neutralizing anti-heparanase monoclonal antibody
US6242195B1 (en)	1998-04-02	2001-06-05	Genentech, Inc.	Methods for determining binding of an analyte to a receptor
US6528624B1 (en) *	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
AU3657899A (en) *	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HU228180B1 (hu)	1998-08-11	2013-01-28	Biogen Idec Inc	Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
US20030217375A1 (en) *	1998-08-31	2003-11-20	Eyal Zcharia	Transgenic animals expressing heparanase and uses thereof
US20010033839A1 (en) *	1999-10-04	2001-10-25	Emilio Barbera-Guillem	Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
US6224866B1 (en)	1998-10-07	2001-05-01	Biocrystal Ltd.	Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DK1616572T3 (da)	1998-11-09	2010-12-06	Biogen Idec Inc	Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
KR20010099788A (ko) *	1998-11-09	2001-11-09	케네쓰 제이. 울코트	Ｂｍｔ 또는 ｐｂｓｃ 이식을 받은 환자의 키메라항-ｃｄ２０ 항체 치료법
WO2000029431A1 (en) *	1998-11-17	2000-05-25	Tanox, Inc.	Bispecific molecules cross-linking itim and itam for therapy
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
KR100940380B1 (ko)	1999-01-15	2010-02-02	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en) *	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
AU2878600A (en) *	1999-03-01	2000-09-21	Hadasit Medical Research Services & Development Company Ltd	Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
JP2002544174A (ja) *	1999-05-07	2002-12-24	ジェネンテック・インコーポレーテッド	Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
EP1645290A1 (en)	1999-05-07	2006-04-12	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
ES2331644T3 (es) *	1999-06-09	2010-01-12	Immunomedics, Inc.	Inmunoterapia de trastornos autoinmunes usando anticuerpos cuya diana son celulas b.
ITMI991299A1 (it) *	1999-06-11	2000-12-11	Consiglio Nazionale Ricerche	Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1189634B1 (en) *	1999-06-25	2007-02-28	Genentech, Inc.	Treating prostate cancer with anti-erbb2 antibodies
US20040013667A1 (en) *	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) *	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
BR0013201A (pt) *	1999-07-12	2002-04-30	Genentech Inc	Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) *	1999-08-11	2002-09-17	Idec Pharmaceuticals Corporation	Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
AU6929100A (en) *	1999-08-23	2001-03-19	Biocrystal Limited	Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
WO2002004021A1 (en) *	2000-07-12	2002-01-17	Idec Pharmaceuticals Corporation	Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) *	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CN1407901A (zh) *	1999-11-08	2003-04-02	Idec药物公司	使用抗cd40l抗体并联合抗cd20抗体和/或化疗剂和放疗治疗b细胞恶性瘤
IL150755A0 (en) *	2000-02-16	2003-02-12	Genentech Inc	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030185796A1 (en) *	2000-03-24	2003-10-02	Chiron Corporation	Methods of therapy for non-hodgkin's lymphoma
BR0109705A (pt) *	2000-03-31	2005-01-11	Idec Pharma Corp	Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
AU2001247616B2 (en)	2000-04-11	2007-06-14	Genentech, Inc.	Multivalent antibodies and uses therefor
EP2264072A1 (en)	2000-04-13	2010-12-22	The Rockefeller University	Enhancement of antibody-mediated cytotoxicity.
WO2001080884A1 (en) *	2000-04-25	2001-11-01	Idec Pharmaceuticals Corporation	Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1280923A2 (en) *	2000-04-28	2003-02-05	Millennium Pharmaceuticals, Inc.	14094, a human trypsin family member and uses thereof
KR20080038458A (ko)	2000-05-19	2008-05-06	제넨테크, 인크.	ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
CA2411102A1 (en) *	2000-06-20	2001-12-27	Idec Pharmaceutical Corporation	Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
JP2003535908A (ja) *	2000-06-22	2003-12-02	アイデックファーマスーティカルズコーポレイション	二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法
US20060034830A1 (en) *	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060029604A1 (en) *	2000-06-28	2006-02-09	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060034828A1 (en) *	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) *	2000-06-28	2006-02-02	Gerngross Tillman U	Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
JP2004508420A (ja) *	2000-09-18	2004-03-18	アイデック　ファーマスーティカルズ　コーポレイション	Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US20020128448A1 (en) *	2000-10-20	2002-09-12	Idec Pharmaceuticals Corporation	Variant IgG3 Rituxan and therapeutic use thereof
US7906492B2 (en) *	2001-01-16	2011-03-15	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US7507724B2 (en) *	2001-01-16	2009-03-24	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
PL364623A1 (en) *	2001-01-17	2004-12-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
AU2008200400B2 (en) *	2001-01-17	2012-06-07	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) *	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US20070065436A1 (en) *	2001-01-31	2007-03-22	Biogen Idec Inc.	Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) *	2002-01-31	2003-11-13	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
CA2436180C (en)	2001-01-31	2011-11-08	Idec Pharmaceutical Corporation	Immunoregulatory antibodies and uses thereof
US20030103971A1 (en) *	2001-11-09	2003-06-05	Kandasamy Hariharan	Immunoregulatory antibodies and uses thereof
CN1494433A (zh)	2001-01-31	2004-05-05	IDECҩ�﹫˾	Cd23拮抗剂用于治疗肿瘤性疾病的用途
US20020159996A1 (en)	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
EP1383800A4 (en) *	2001-04-02	2004-09-22	Idec Pharma Corp	RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
AU2002250352C1 (en)	2001-04-02	2009-04-30	Genentech, Inc.	Combination therapy
WO2002080987A1 (en) *	2001-04-09	2002-10-17	Progenics Pharmaceuticals, Inc.	Anti-cd19 immunotoxins
US20020193569A1 (en) *	2001-06-04	2002-12-19	Idec Pharmaceuticals Corporation	Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
AU2002316230A1 (en) *	2001-06-13	2002-12-23	Genentech, Inc.	Methods of culturing animal cells and polypeptide production in animal cells
KR20040054669A (ko) *	2001-08-03	2004-06-25	글리카트 바이오테크놀로지 아게	항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
PL377119A1 (pl) *	2001-08-03	2006-01-23	Genentech, Inc.	Peptydy TACIs i BR3 i ich zastosowanie
US7255858B2 (en) *	2001-08-10	2007-08-14	University Of Virginia Patent Foundation	Enhancing the efficacy of immunotherapies by supplementing with complement
US7214428B2 (en) *	2001-09-17	2007-05-08	Invitrogen Corporation	Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
US7205048B2 (en)	2001-09-17	2007-04-17	Invitrogen Corporation	Functionalized fluorescent nanocrystal compositions and methods of making
US6955855B2 (en) *	2001-09-17	2005-10-18	Biocrystal, Ltd.	Nanocrystals
ATE443259T1 (de)	2001-09-20	2009-10-15	Univ Texas	Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
EP2305312B1 (en)	2001-10-10	2015-03-04	ratiopharm GmbH	Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
US20050069962A1 (en)	2001-10-12	2005-03-31	Archer Robert M	Antibody complexes and methods for immunolabeling
US8323903B2 (en) *	2001-10-12	2012-12-04	Life Technologies Corporation	Antibody complexes and methods for immunolabeling
DE02782887T1 (de) *	2001-10-19	2005-01-13	Centre Hospitalier Regional et Universitair de Tours	Methoden und kompositionen, antikörper behandlung zu bewerten
US20030157108A1 (en) *	2001-10-25	2003-08-21	Genentech, Inc.	Glycoprotein compositions
US6671189B2 (en) *	2001-11-09	2003-12-30	Minebea Co., Ltd.	Power converter having primary and secondary side switches
EP2022799A2 (en)	2001-11-16	2009-02-11	Biogen Idec Inc.	Polycistronic expression of antibodies
US20060024292A1 (en) *	2001-12-27	2006-02-02	Gerngross Tillman U	Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
DE60325334D1 (de)	2002-02-05	2009-01-29	Genentech Inc	Proteinaufreinigung
US20040005298A1 (en)	2002-02-08	2004-01-08	Xcyte Therapies, Inc.	Compositions and methods for restoring immune responsiveness in patients with immunological defects
CN101914158A (zh) *	2002-02-14	2010-12-15	免疫医疗公司	抗cd 20抗体及其融合蛋白和使用方法
US8287864B2 (en) *	2002-02-14	2012-10-16	Immunomedics, Inc.	Structural variants of antibodies for improved therapeutic characteristics
US20040002587A1 (en) *	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US8361464B2 (en)	2002-03-01	2013-01-29	Immunomedics, Inc.	Anthracycline-Antibody Conjugates for Cancer Therapy
US7662925B2 (en) *	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
ATE477276T1 (de) *	2002-03-01	2010-08-15	Immunomedics Inc	Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20030180292A1 (en) *	2002-03-14	2003-09-25	Idec Pharmaceuticals	Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
HUE025101T2 (en)	2002-04-26	2016-02-29	Genentech Inc	Purification of proteins other than affinity purification
MXPA05000940A (es) *	2002-07-25	2005-05-16	Genentech Inc	Anticuerpos taci y su uso.
US8044180B2 (en) *	2002-08-14	2011-10-25	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) *	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) *	2002-08-14	2012-06-05	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en)	2002-08-14	2015-03-03	Macrogenics Inc.	FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) *	2002-08-14	2012-05-29	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
DK1553975T3 (da)	2002-09-27	2012-05-07	Xencor Inc	Optimerede Fc-varianter og fremgangsmåder til generering heraf.
WO2004035607A2 (en) *	2002-10-17	2004-04-29	Genmab A/S	Human monoclonal antibodies against cd20
JP4033390B2 (ja) *	2002-10-30	2008-01-16	独立行政法人科学技術振興機構	不死化ナチュラルキラー細胞株
CA2506320A1 (en) *	2002-11-21	2004-06-10	Genentech, Inc.	Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
SE0203731D0 (sv) *	2002-12-13	2002-12-13	Mitra Medical Technology Ab	Reagent
EP2301966A1 (en) *	2002-12-16	2011-03-30	Genentech, Inc.	Immunoglobulin variants and uses thereof
EP2368578A1 (en) *	2003-01-09	2011-09-28	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) *	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
JP4177123B2 (ja) *	2003-01-10	2008-11-05	富士通株式会社	配線図形検証方法、プログラム及び装置
US20040202666A1 (en) *	2003-01-24	2004-10-14	Immunomedics, Inc.	Anti-cancer anthracycline drug-antibody conjugates
AU2004207538A1 (en) *	2003-01-27	2004-08-12	Biogen Idec Ma Inc.	Compositions and methods for treating cancer using IGSF9 and LIV-1
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) *	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
AU2004229376B2 (en)	2003-04-09	2007-12-13	Genentech, Inc.	Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
CN1802388B (zh) *	2003-05-09	2011-01-05	杜克大学	Cd20特异抗体及使用它们的方法
BRPI0411276A (pt)	2003-06-05	2006-08-01	Genentech Inc	métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
WO2004108065A2 (en) *	2003-06-09	2004-12-16	Insight Biopharmaceuticals Ltd.	Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
ES2786568T3 (es)	2003-07-28	2020-10-13	Genentech Inc	Reducción de la lixiviación de la proteína A durante la cromatografía de afinidad con proteína A
ZA200600798B (en) *	2003-07-29	2007-06-27	Genentech Inc	Assay for human anti CD20 antibodies and uses therefor
WO2005023302A2 (en) *	2003-08-29	2005-03-17	Genentech, Inc.	Anti-cd20 therapy of ocular disorders
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US8883147B2 (en)	2004-10-21	2014-11-11	Xencor, Inc.	Immunoglobulins insertions, deletions, and substitutions
US20060134105A1 (en) *	2004-10-21	2006-06-22	Xencor, Inc.	IgG immunoglobulin variants with optimized effector function
US8399618B2 (en)	2004-10-21	2013-03-19	Xencor, Inc.	Immunoglobulin insertions, deletions, and substitutions
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US8076459B2 (en)	2003-10-16	2011-12-13	Micromet Ag	Multispecfic deimmunized CD3-binders
PT1684869E (pt)	2003-11-04	2011-09-16	Novartis Vaccines & Diagnostic	Métodos de terapêutica para cancros relacionados com células b
BRPI0416243A (pt) *	2003-11-05	2007-01-09	Palingen Inc	método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
ME02332B (me) *	2003-11-05	2016-06-30	Roche Glycart Ag	Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za Fc receptor i efektornom funkcijom
CA2545603A1 (en)	2003-11-12	2005-05-26	Biogen Idec Ma Inc.	Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US7750123B2 (en) *	2003-11-25	2010-07-06	Dana Farber Cancer Institute, Inc.	Antibodies against SARS-CoV and methods of use thereof
BRPI0417105A (pt) *	2003-12-19	2007-02-06	Genentech Inc	métodos de tratamento de doenças autoimunológicas em pacientes
BRPI0417108A (pt) *	2003-12-19	2007-02-06	Genentech Inc	métodos de tratamento de rejeições de transplantes em pacientes
FR2867982B1 (fr) *	2004-03-26	2007-07-20	Jean Marie Andrieu	Procede pour amplifier l'activite de vaccins therapeutiques
ZA200608572B (en) *	2004-04-16	2008-06-25	Genentech Inc	Assay for antibodies
WO2005113003A2 (en) *	2004-04-16	2005-12-01	Genentech, Inc.	Method for augmenting b cell depletion
WO2005115453A2 (en) *	2004-04-16	2005-12-08	Genentech, Inc.	Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
US7850962B2 (en) *	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
BRPI0510224A (pt) *	2004-05-05	2007-10-23	Genentech Inc	métodos de prevenção de doença autoimunológica e artigo industrializado
ES2390278T3 (es)	2004-05-20	2012-11-08	Zymogenetics, Inc.	Procedimientos de tratamiento del cáncer usando tratamiento con IL-21 y anticuerpos monoclonales
PA8635501A1 (es) *	2004-06-04	2006-06-02	Genentech Inc	Uso de un anticuerpo para el tratamiento del lupus
CN102512675A (zh) *	2004-06-04	2012-06-27	健泰科生物技术公司	用于治疗多发性硬化的方法
US9109255B2 (en) *	2004-06-18	2015-08-18	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for determining responsiveness to antibody therapy
DK2471813T3 (en)	2004-07-15	2015-03-02	Xencor Inc	Optimized Fc variants
US20060062787A1 (en) *	2004-07-22	2006-03-23	Genentech, Inc.	Method for treating Sjogren's syndrome
EP1771476B1 (en)	2004-07-23	2014-12-10	Genentech, Inc.	Crystallization of anti-vegf antibodies
KR100864549B1 (ko)	2004-08-04	2008-10-20	어플라이드 몰리큘라 에볼류션, 인코포레이티드	변이체 ｆｃ 영역
JP2008510852A (ja) *	2004-08-17	2008-04-10	インヴィトロジェンコーポレーション	高発光性コロイド粒子の合成
CN101052654A (zh) *	2004-08-19	2007-10-10	健泰科生物技术公司	具有改变的效应子功能的多肽变体
US7662926B2 (en) *	2004-09-02	2010-02-16	Genentech, Inc.	Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
WO2006028956A2 (en) *	2004-09-02	2006-03-16	Genentech, Inc.	Anti-fc-gamma riib receptor antibody and uses therefor
US7655229B2 (en) *	2004-09-02	2010-02-02	Chan Andrew C	Anti-FC-gamma RIIB receptor antibody and uses therefor
US20090175854A1 (en) *	2004-09-08	2009-07-09	Genentech, Inc.	Methods of using death receptor ligands and CD20 antibodies
BRPI0515615A (pt) *	2004-09-08	2008-07-29	Genentech Inc	métodos para tratar células cancerosas e doença imune relacionada
CN101087807A (zh) *	2004-10-05	2007-12-12	健泰科生物技术公司	治疗血管炎的方法
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
EP2305775A3 (en)	2004-10-29	2011-06-08	Molecular Probes, Inc.	Functionalized fluorescent nanocrystals, and methods for their preparation and use
CA2587766A1 (en) *	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US20070135620A1 (en) *	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
US8367805B2 (en) *	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
EP2845865A1 (en)	2004-11-12	2015-03-11	Xencor Inc.	Fc variants with altered binding to FcRn
GB2420976B (en) *	2004-11-19	2006-12-20	Zvi Finkelstein	Therapeutic implant
JP2008524241A (ja) *	2004-12-17	2008-07-10	ジェネンテック・インコーポレーテッド	従来の治療の効果がなかった患者の自己免疫性疾患の血管新生阻害治療
EP1674479A1 (en) *	2004-12-22	2006-06-28	Memorial Sloan-Kettering Cancer Center	Modulation of Fc Gamma receptors for optimizing immunotherapy
EP2290088A1 (en)	2004-12-22	2011-03-02	Genentech, Inc.	Methods for producing soluble multi-menbrane-spanning proteins
DE602004021404D1 (de)	2004-12-23	2009-07-16	Gpc Biotech Ag	Quadratsäurederivate mit antiproliferativer Wirkung
US7955806B2 (en) *	2004-12-23	2011-06-07	Hoffmann—La Roche Inc.	Detection of a therapeutic antibody in an experimental animal
EP2311880A3 (en)	2005-01-05	2011-07-27	Biogen Idec MA Inc.	Cripto binding molecules
CA2590163A1 (en) *	2005-01-13	2006-07-20	Genentech, Inc.	Treatment method
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8475794B2 (en)	2005-04-06	2013-07-02	Ibc Pharmaceuticals, Inc.	Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en)	2005-04-06	2013-01-08	Ibc Pharmaceuticals, Inc.	Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
EP3479844B1 (en) *	2005-04-15	2023-11-22	MacroGenics, Inc.	Covalent diabodies and uses thereof
US11254748B2 (en)	2005-04-15	2022-02-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
AR053579A1 (es) *	2005-04-15	2007-05-09	Genentech Inc	Tratamiento de la enfermedad inflamatoria intestinal (eii)
US9284375B2 (en) *	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
EP1874350A2 (en) *	2005-04-22	2008-01-09	Genentech, Inc.	Method for treating dementia or alzheimer's disease with a cd20 antibody
US8034902B2 (en) *	2005-05-04	2011-10-11	Quark Pharmaceuticals, Inc.	Recombinant antibodies against CD55 and CD59 and uses thereof
MX2007013924A (es) *	2005-05-09	2008-01-28	Glycart Biotechnology Ag	Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
KR20080046135A (ko) *	2005-05-20	2008-05-26	제넨테크, 인크.	자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
BRPI0610203A2 (pt) *	2005-05-24	2010-06-01	Avestha Gengraine Tech Pvt Ltd	processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica
CN101495509B (zh)	2005-07-08	2015-04-22	比奥根艾迪克Ma公司	Sp35抗体及其用途
KR101251157B1 (ko)	2005-07-25	2013-04-10	이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨	Ｃｄ37-특이적 결합 분자 및 ｃｄ20-특이적 결합 분자를사용한 ｂ-세포 감소
US20080279850A1 (en) *	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
EP2415483A1 (en)	2005-07-25	2012-02-08	Emergent Product Development Seattle, LLC	Single dose use of cd20-specific binding molecules
LT2573114T (lt)	2005-08-10	2016-10-10	Macrogenics, Inc.	Atpažinimas ir konstravimas antikūnų su variantinėmis fc sritimis ir jų panaudojimo būdai
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
CA2618482C (en)	2005-08-19	2014-10-07	Abbott Laboratories	Dual variable domain immunoglobin and uses thereof
EP2500356A3 (en)	2005-08-19	2012-10-24	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
WO2007028144A2 (en) *	2005-09-02	2007-03-08	Glycofi, Inc	Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
EP1931709B1 (en)	2005-10-03	2016-12-07	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
US20070161089A1 (en) *	2005-11-08	2007-07-12	Genentech, Inc.	Method of Producing Pan-Specific Antibodies
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
EP1952150B1 (en) *	2005-11-23	2016-12-14	Genentech, Inc.	Methods and compositions related to b cell assays
US20070136826A1 (en) *	2005-12-02	2007-06-14	Biogen Idec Inc.	Anti-mouse CD20 antibodies and uses thereof
US8323644B2 (en) *	2006-01-17	2012-12-04	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
WO2007102200A1 (ja)	2006-03-07	2007-09-13	Osaka University	抗ｃｄ２０モノクローナル抗体
CA2644903A1 (en) *	2006-03-10	2007-09-20	Macrogenics, Inc.	Identification and engineering of antibodies with variant heavy chains and methods of using same
RU2008141912A (ru)	2006-03-23	2010-04-27	Новартис АГ (CH)	Противоопухолевые лекарства на основе антител к клеточным антигенам
CA2650730A1 (en)	2006-04-27	2007-11-08	Pikamab, Inc.	Methods and compositions for antibody therapy
US20080118978A1 (en)	2006-04-28	2008-05-22	Takashi Sato	Anti-tumor agent
US7727525B2 (en) *	2006-05-11	2010-06-01	City Of Hope	Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
ES2489646T3 (es) *	2006-05-26	2014-09-02	Macrogenics, Inc.	Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
EP2041178A2 (en) *	2006-06-12	2009-04-01	Trubion Pharmaceuticals, Inc.	Single-chain multivalent binding proteins with effector function
CA2656224C (en) *	2006-06-26	2018-01-09	Macrogenics, Inc.	Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
WO2008019199A2 (en) *	2006-06-26	2008-02-14	Macrogenics, Inc.	FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
FR2902799B1 (fr)	2006-06-27	2012-10-26	Millipore Corp	Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8372399B2 (en) *	2006-08-31	2013-02-12	Cardiac Pacemakers, Inc.	Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) *	2006-08-31	2014-01-28	Cardiac Pacemakers, Inc.	Methods and devices to regulate stem cell homing
US20080058922A1 (en) *	2006-08-31	2008-03-06	Cardiac Pacemakers, Inc.	Methods and devices employing vap-1 inhibitors
US20080112961A1 (en) *	2006-10-09	2008-05-15	Macrogenics, Inc.	Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US9382327B2 (en)	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
WO2008140603A2 (en)	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8362217B2 (en) *	2006-12-21	2013-01-29	Emd Millipore Corporation	Purification of proteins
US8163886B2 (en) *	2006-12-21	2012-04-24	Emd Millipore Corporation	Purification of proteins
US8569464B2 (en)	2006-12-21	2013-10-29	Emd Millipore Corporation	Purification of proteins
PT2436696T (pt)	2007-01-05	2017-08-21	Univ Zuerich	Anticorpo anti-beta-amiloide e usos do mesmo
DE102007001370A1 (de) *	2007-01-09	2008-07-10	Curevac Gmbh	RNA-kodierte Antikörper
GEP20125693B (en)	2007-01-09	2012-11-26	Biogen Idec Inc	Sp35 antibodies and usage thereof
ES2374330T3 (es)	2007-01-22	2012-02-15	Genentech, Inc.	Precipitación con polielectrolito y purificación de anticuerpos.
US8450348B2 (en) *	2007-02-21	2013-05-28	Forma Tm, Llc	Derivatives of squaric acid with anti-proliferative activity
IN2009DN05758A (pt) *	2007-03-12	2015-07-24	Esbatech Ag
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (en) *	2007-04-02	2008-10-09	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Selenocysteine mediated hybrid antibody molecules
FR2915398B1 (fr) *	2007-04-25	2012-12-28	Lab Francais Du Fractionnement	"ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1995309A1 (en) *	2007-05-21	2008-11-26	Vivalis	Recombinant protein production in avian EBx® cells
EP2019101A1 (en) *	2007-07-26	2009-01-28	GPC Biotech AG	Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
PT2164961E (pt) *	2007-06-25	2015-04-08	Esbatech Alcon Biomed Res Unit	Manipulação baseada em sequências e otimização de anticorpos de cadeia única
HUE027507T2 (en) *	2007-06-25	2016-10-28	Esbatech Alcon Biomed Res Unit	Procedures for Modifying Antibodies and Modified Antibodies with Improved Functional Properties
US20090324596A1 (en)	2008-06-30	2009-12-31	The Trustees Of Princeton University	Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en)	2007-06-28	2020-08-18	The Trustees Of Princeton University	Methods of identifying and treating poor-prognosis cancers
DK3597659T5 (da)	2007-07-09	2024-09-02	Genentech Inc	Forhindring af disulfidbindingsreduktion under rekombinant produktion af polypeptider
EP2178916B1 (en) *	2007-07-31	2014-12-17	Regeneron Pharmaceuticals, Inc.	Human antibodies to human cd20 and method of using thereof
AU2008295140A1 (en) *	2007-09-05	2009-03-12	F. Hoffmann-La Roche Ag	Combination therapy with type I and type II anti-CD20 antibodies
EP2205249B1 (en)	2007-09-28	2018-11-07	Intrexon Corporation	Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US20090098118A1 (en) *	2007-10-15	2009-04-16	Thomas Friess	Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
EP2233149B1 (en)	2007-10-16	2016-02-10	ZymoGenetics, Inc.	Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
WO2009052617A1 (en) *	2007-10-22	2009-04-30	Oncolytics Biotech Inc.	Treatment regime for proliferative disorders
US20090110688A1 (en) *	2007-10-24	2009-04-30	Georg Fertig	Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
KR20150008503A (ko)	2007-10-30	2015-01-22	제넨테크, 인크.	양이온 교환 크로마토그래피에 의한 항체 정제
US8795667B2 (en) *	2007-12-19	2014-08-05	Macrogenics, Inc.	Compositions for the prevention and treatment of smallpox
JP2011507897A (ja) *	2007-12-21	2011-03-10	ジェネンテック，インコーポレイテッド	リツキシマブ抵抗性関節リウマチ患者の治療
CN105418762B (zh)	2007-12-26	2019-11-05	Xencor公司	与FcRn结合改变的Fc变体
EP2077281A1 (en)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2085095B1 (en)	2008-01-17	2012-03-07	Philogen S.p.A.	Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
ES2613963T3 (es)	2008-01-18	2017-05-29	Medimmune, Llc	Anticuerpos manipulados con cisteína para conjugación específica de sitio
US8883155B2 (en) *	2008-01-28	2014-11-11	The Regents Of The University Of California	Methods for treating hematopoietic malignancies
CN107198772A (zh) *	2008-03-25	2017-09-26	罗氏格黎卡特股份公司	Ii型抗cd20抗体与环磷酰胺、长春新碱和多柔比星联合治疗非霍奇金淋巴瘤的应用
WO2009123894A2 (en)	2008-04-02	2009-10-08	Macrogenics, Inc.	Her2/neu-specific antibodies and methods of using same
US8669349B2 (en)	2008-04-02	2014-03-11	Macrogenics, Inc.	BCR-complex-specific antibodies and methods of using same
RU2531754C2 (ru)	2008-04-11	2014-10-27	ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US	Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
EP2112152A1 (en)	2008-04-22	2009-10-28	GPC Biotech AG	Dihydropteridinones as Plk Inhibitors
EP2112150B1 (en)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Improved raf inhibitors
BRPI0910482A2 (pt)	2008-04-29	2019-09-24	Abbott Lab	imunoglobinas de domínio variável duplo e usos das mesmas
US20090269339A1 (en) *	2008-04-29	2009-10-29	Genentech, Inc.	Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
TW201006485A (en) *	2008-06-03	2010-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) *	2008-06-03	2013-07-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CA2726845C (en) *	2008-06-04	2017-09-26	Macrogenics, Inc.	Antibodies with altered binding to fcrn and methods of using same
WO2009151514A1 (en) *	2008-06-11	2009-12-17	Millipore Corporation	Stirred tank bioreactor
DK3241843T3 (da)	2008-06-25	2021-09-06	Novartis Ag	Opløselighedsoptimering af immunbindere
WO2010003057A2 (en)	2008-07-03	2010-01-07	Mayo Foundation For Medical Education And Research	Treating cancer
KR101054362B1 (ko)	2008-07-03	2011-08-05	재단법인 목암생명공학연구소	재조합 단백질의 푸코스 함량을 감소시키는 방법
AU2009268585C1 (en) *	2008-07-08	2014-10-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8058406B2 (en)	2008-07-09	2011-11-15	Biogen Idec Ma Inc.	Composition comprising antibodies to LINGO or fragments thereof
KR101030978B1 (ko) *	2008-07-10	2011-04-28	(주) 에이프로젠	동물세포용 재조합 발현벡터
JP5986745B2 (ja)	2008-07-15	2016-09-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US20100021460A1 (en) *	2008-07-15	2010-01-28	Genentech, Inc.	Methods of Treating Autoimmune Diseases Using CD4 Antibodies
EA201100228A1 (ru) *	2008-07-21	2011-08-30	Иммьюномедикс, Инк.	Структурные варианты антител для улучшения терапевтических характеристик
US8900851B2 (en) *	2008-07-22	2014-12-02	The Research Foundation For The State University Of New York	Multi-well platform
RS59232B1 (sr)	2008-08-14	2019-10-31	Genentech Inc	Postupci za uklanjanje zagađivača koristeći hromatografiju membrane razmene jona sa razmeštanjem autohtonih proteina
CA2734275A1 (en)	2008-09-10	2010-03-18	Genentech, Inc.	Compositions and methods for the prevention of oxidative degradation of proteins
TW201438738A (zh)	2008-09-16	2014-10-16	Genentech Inc	治療進展型多發性硬化症之方法
AP2011005739A0 (en) *	2008-10-28	2011-06-30	Avesthagen Ltd	An expression vector and processes thereof.
US20100233079A1 (en) *	2008-12-04	2010-09-16	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
GB2466025A (en)	2008-12-08	2010-06-09	Univ Francois Rabelais De Tour	C3/ITGAM polymorphisms and cancer prognosis
WO2010068722A1 (en)	2008-12-12	2010-06-17	Medimmune, Llc	Crystals and structure of a human igg fc variant with enhanced fcrn binding
JP2012511929A (ja)	2008-12-16	2012-05-31	イー・エム・デイー・ミリポア・コーポレイシヨン	攪拌タンク反応器及び方法
SG171764A1 (en) *	2008-12-16	2011-07-28	Millipore Corp	Purification of proteins
PL2370466T3 (pl)	2008-12-19	2015-12-31	Biogen Int Neuroscience Gmbh	Ludzkie autoprzeciwciała anty-alfa-synukleina
MX2011006725A (es)	2008-12-22	2011-09-15	Millennium Pharm Inc	Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
AU2009334498A1 (en)	2008-12-31	2011-07-21	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
US20110142836A1 (en) *	2009-01-02	2011-06-16	Olav Mella	B-cell depleting agents for the treatment of chronic fatigue syndrome
JP5828151B6 (ja)	2009-01-06	2018-09-19	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	アテローム性動脈硬化の処置のためのｂ細胞枯渇剤
EP2400992B1 (en)	2009-02-27	2015-07-22	Genentech, Inc.	Methods and compositions for protein labelling
JP5836807B2 (ja)	2009-03-05	2015-12-24	アッヴィ・インコーポレイテッド	Ｉｌ−１７結合タンパク質
MX341884B (es)	2009-03-10	2016-09-07	Biogen Ma Inc	Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
JP5709766B2 (ja)	2009-03-12	2015-04-30	ジェネンテック，インコーポレイテッド	造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
EP2233500A1 (en)	2009-03-20	2010-09-29	LFB Biotechnologies	Optimized Fc variants
RU2542394C2 (ru)	2009-03-24	2015-02-20	ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК.	Гуманизированные антитела против light и их применение
US20100247484A1 (en)	2009-03-31	2010-09-30	Heinrich Barchet	Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
EP2435476A4 (en) *	2009-05-27	2013-04-17	Synageva Biopharma Corp	ANTIBODIES OBTAINED FROM BIRDS
EP2443234B1 (en)	2009-06-15	2018-08-15	Icon Genetics GmbH	Nicotiana benthamiana plants deficient in xylosyltransferase activity
EP2711018A1 (en)	2009-06-22	2014-03-26	MedImmune, LLC	Engineered Fc regions for site-specific conjugation
WO2011000543A1 (en) *	2009-06-30	2011-01-06	Philochem Ag	Murine antibody display library
UY32808A (es) *	2009-07-29	2011-02-28	Abbott Lab	Inmunoglobulinas como dominio variable dual y usos de las mismas
MX2012001742A (es)	2009-08-11	2012-03-21	Genentech Inc	Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
TWI409079B (zh)	2009-08-14	2013-09-21	Roche Glycart Ag	非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
NZ597325A (en)	2009-08-14	2014-03-28	Roche Glycart Ag	Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
US9428548B2 (en)	2009-09-01	2016-08-30	Genentech, Inc.	Enhanced protein purification through a modified protein A elution
US8586714B2 (en)	2009-09-01	2013-11-19	Abbvie, Inc.	Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RU2539112C2 (ru)	2009-09-03	2015-01-10	Дженентек, Инк.	Способы лечения, диагностики и мониторинга ревматоидного артрита
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2486141B1 (en)	2009-10-07	2018-01-10	MacroGenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
PE20121531A1 (es)	2009-10-15	2012-12-22	Abbott Lab	Inmunoglobulinas con dominio variable dual
MX337290B (es) *	2009-10-19	2016-02-24	Hoffmann La Roche	Anticuerpos anti igg reactivos no cruzados.
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2325185A1 (en)	2009-10-28	2011-05-25	GPC Biotech AG	Plk inhibitor
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
WO2011097527A2 (en)	2010-02-04	2011-08-11	Xencor, Inc.	Immunoprotection of therapeutic moieties using enhanced fc regions
US20120309056A1 (en)	2010-02-04	2012-12-06	Leon Arnaud	Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
US20110189178A1 (en) *	2010-02-04	2011-08-04	Xencor, Inc.	Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
US9175086B2 (en) *	2010-02-10	2015-11-03	Immunogen, Inc.	CD20 antibodies and uses thereof
KR20130009760A (ko)	2010-02-10	2013-01-23	이뮤노젠 아이엔씨	Ｃｄ２０ 항체 및 이의 용도
AU2011222012C1 (en)	2010-03-02	2015-02-26	Kyowa Kirin Co., Ltd.	Modified antibody composition
MA34062B1 (fr)	2010-03-04	2013-03-05	Macrogenics Inc	Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR20180000342A (ko)	2010-03-22	2018-01-02	제넨테크, 인크.	단백질-함유 제제의 안정화에 유용한 조성물 및 방법
EP2554669B1 (en)	2010-03-26	2018-09-19	Kyowa Hakko Kirin Co., Ltd.	Novel antibody having modification site introduced therein, and antibody fragment
US9169328B2 (en)	2010-03-26	2015-10-27	Memorial Sloan Kettering Cancer Center	Antibodies to MUC16 and methods of use thereof
EP2552957A4 (en)	2010-03-29	2013-11-20	Zymeworks Inc	ANTIBODIES WITH REINFORCED OR SUPPRESSIVE ACTIVE FUNCTION
ES2993140T3 (en)	2010-04-02	2024-12-23	Amunix Pharmaceuticals Inc	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
EP2563391B1 (en)	2010-04-27	2020-08-26	Roche Glycart AG	Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
BR112012027828A2 (pt)	2010-05-03	2016-08-09	Genentech Inc	composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP2975409B1 (en)	2010-05-10	2018-10-31	Academia Sinica	Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
KR101848225B1 (ko)	2010-05-14	2018-04-12	애브비 인코포레이티드	Ｉｌ－１ 결합 단백질
SG10201804385YA (en)	2010-05-17	2018-06-28	Emd Millipore Corp	Stimulus responsive polymers for the purification of biomolecules
SG10201710439UA (en)	2010-05-25	2018-01-30	Genentech Inc	Methods of purifying polypeptides
WO2011150241A2 (en)	2010-05-28	2011-12-01	Genentech, Inc.	Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
KR102058307B1 (ko)	2010-06-24	2019-12-20	제넨테크, 인크.	단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
WO2012006500A2 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103180439A (zh)	2010-07-09	2013-06-26	比奥根艾迪克依蒙菲利亚公司	嵌合凝血因子
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
CN105585630B (zh)	2010-07-29	2020-09-15	Xencor公司	具有修改的等电点的抗体
EP2601216B1 (en)	2010-08-02	2018-01-03	MacroGenics, Inc.	Covalent diabodies and uses thereof
JPWO2012017925A1 (ja)	2010-08-02	2013-10-03	協和発酵キリン株式会社	物質の製造方法
CN103153341B (zh)	2010-08-03	2015-05-27	霍夫曼-拉罗奇有限公司	慢性淋巴细胞性白血病(cll)生物标志物
JP2013537415A (ja)	2010-08-03	2013-10-03	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリンおよびその使用
EP2600901B1 (en)	2010-08-06	2019-03-27	ModernaTX, Inc.	A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013003279A2 (pt)	2010-08-13	2016-06-14	Genentech In	“métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
CA2806851C (en) *	2010-08-17	2019-12-03	F. Hoffmann-La Roche Ag	Anti-human igg1 antibody
TW201208703A (en)	2010-08-17	2012-03-01	Roche Glycart Ag	Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
PH12013500337A1 (en)	2010-08-26	2017-08-23	Abbvie Inc	Dual variable domain immunoglobulins and uses thereof
WO2012030512A1 (en)	2010-09-03	2012-03-08	Percivia Llc.	Flow-through protein purification process
BR112013007862A2 (pt)	2010-10-01	2019-09-24	Moderna Therapeutics Inc	ácidos nucleicos manipulados e métodos de uso dos mesmos.
JP2014503178A (ja)	2010-10-11	2014-02-13	バイオジェンアイデックインターナショナルニューロサイエンスゲーエムベーハー	ヒト抗タウ抗体
KR20190120439A (ko)	2010-11-08	2019-10-23	제넨테크, 인크.	피하 투여용 항―ｉｌ―6 수용체 항체
ES2661981T3 (es)	2010-12-15	2018-04-04	Inter-University Research Institute Corporation Research Organization Of Information And Systems	Procedimiento de producción de una proteína
CN103261229A (zh)	2010-12-16	2013-08-21	罗切格利卡特公司	无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
EP2651979B1 (en)	2010-12-17	2019-08-28	Neurimmune Holding AG	Human anti-sod1 antibodies
TW201249865A (en)	2010-12-21	2012-12-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
WO2012091023A1 (ja)	2010-12-27	2012-07-05	協和発酵キリン株式会社	培地およびキレート剤を含む水溶液の調製方法
WO2012095514A1 (en)	2011-01-14	2012-07-19	Vivalis	Recombinant protein production system
US9433686B2 (en)	2011-01-31	2016-09-06	The Regents Of The University Of California	Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
WO2012118750A2 (en)	2011-02-28	2012-09-07	Genentech, Inc.	Biological markers and methods for predicting response to b-cell antagonists
TWI588156B (zh)	2011-03-28	2017-06-21	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
DK2691417T4 (en)	2011-03-29	2025-01-02	Roche Glycart Ag	Antistof fc-varianter
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
EP2506015A1 (en)	2011-04-01	2012-10-03	Universität Regensburg	A prognostic and therapeutic signature for malignant melanoma
TR201905909T4 (tr)	2011-04-19	2019-05-21	Pfizer	Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
US9427477B2 (en)	2011-05-09	2016-08-30	Mayo Foundation For Medical Education And Research	Cancer treatments
EP2707723B1 (en)	2011-05-12	2016-02-10	Genentech, Inc.	Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
JP6400470B2 (ja)	2011-05-16	2018-10-03	ジェネロン（シャンハイ）コーポレイションリミテッド	多重特異性Ｆａｂ融合タンパク質および使用法
NZ618016A (en)	2011-05-21	2015-05-29	Macrogenics Inc	Deimmunized serum-binding domains and their use for extending serum half-life
SMT201900239T1 (it)	2011-05-21	2019-05-10	Macrogenics Inc	Molecole di legame a cd3 in grado di legare cd3 umano e non umano
RU2011122942A (ru)	2011-06-08	2012-12-20	Общество С Ограниченной Ответственностью "Асинэкс Медхим"	Новые ингибиторы киназ
WO2012177972A1 (en)	2011-06-23	2012-12-27	Biogen Idec International Neuroscience Gmbh	Anti-alpha synuclein binding molecules
EP2537933A1 (en)	2011-06-24	2012-12-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CA2839513A1 (en)	2011-07-06	2013-01-10	Morphosys Ag	Therapeutic combinations of anti - cd20 and anti - gm - csf antibodies and uses thereof
KR20140004231A (ko)	2011-07-08	2014-01-10	이엠디 밀리포어 코포레이션	일회용 생명공학적 공정용의 개선된 심층 필터
WO2019071023A1 (en)	2017-10-04	2019-04-11	Yale University	COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
WO2013009868A1 (en)	2011-07-11	2013-01-17	Yale University	Compositions and methods for making selenocysteine containing polypeptides
WO2013012733A1 (en)	2011-07-15	2013-01-24	Biogen Idec Ma Inc.	Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
EP2550975A1 (en)	2011-07-29	2013-01-30	Sanofi	Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
EP2551348B1 (en)	2011-07-29	2014-09-24	Icon Genetics GmbH	Production of galactosylated N-glycans in plants
WO2013022855A1 (en)	2011-08-05	2013-02-14	Xencor, Inc.	Antibodies with modified isoelectric points and immunofiltering
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
WO2013049362A2 (en)	2011-09-27	2013-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
KR102014061B1 (ko)	2011-10-03	2019-08-28	모더나 세라퓨틱스, 인코포레이티드	변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
AU2012320847B2 (en)	2011-10-04	2018-03-08	Icon Genetics Gmbh	Nicotiana benthamiana plants deficient in fucosyltransferase activity
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2012323287B2 (en)	2011-10-10	2018-02-01	Xencor, Inc.	A method for purifying antibodies
SG11201401791WA (en)	2011-10-24	2014-08-28	Abbvie Inc	Immunobinders directed against sclerostin
BR112014010008A2 (pt)	2011-10-26	2018-09-04	Novartis Ag	anticorpos monoclonais, seus usos e ácidos nucleicos
US20130302274A1 (en)	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
RS63244B1 (sr)	2011-12-16	2022-06-30	Modernatx Inc	Kompozicije modifikovane mrna
RU2648999C2 (ru)	2011-12-22	2018-03-29	Дженентек, Инк.	Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
AR089529A1 (es)	2011-12-30	2014-08-27	Abbvie Inc	Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
US20130243750A1 (en)	2012-01-31	2013-09-19	Genentech, Inc.	Anti-ige antibodies and methods using same
CN104334196B (zh)	2012-02-16	2018-04-10	Atyr 医药公司	用于治疗自身免疫疾病和炎性疾病的组氨酰‑tRNA合成酶
WO2013148249A1 (en)	2012-03-27	2013-10-03	Genentech, Inc.	Improved harvest operations for recombinant proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9192651B2 (en)	2012-04-02	2015-11-24	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of secreted proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
NZ702178A (en)	2012-05-14	2017-01-27	Biogen Ma Inc	Lingo-2 antagonists for treatment of conditions involving motor neurons
DK2859017T3 (da)	2012-06-08	2019-05-13	Sutro Biopharma Inc	Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
EP2863940A4 (en)	2012-06-08	2016-08-10	Biogen Ma Inc	CHIMERIC COAGULATION FACTORS
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
SI3495387T1 (sl)	2012-07-13	2021-12-31	Roche Glycart Ag	Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
CA2880701A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en)	2012-08-21	2017-01-17	Academia Sinica	Benzocyclooctyne compounds and uses thereof
EP4074728A1 (en)	2012-08-31	2022-10-19	Sutro Biopharma, Inc.	Modified peptides comprising an azido group
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014052713A2 (en)	2012-09-27	2014-04-03	Massachusetts Institute Of Technology	Her2-and vegf-a-binding proteins with enhanced stability
EP2903610B1 (en)	2012-10-01	2021-11-03	Mayo Foundation For Medical Education And Research	Cancer treatments
US20150238602A1 (en)	2012-10-09	2015-08-27	Biogen Idec Ma Inc.	Combination therapies and uses for treatment of demyelinating disorders
TR201910662T4 (tr)	2012-10-12	2019-08-21	Medimmune Ltd	Pirrolobenzodiazepinler ve bunlara ait konjugatlar.
TW201838651A (zh)	2012-11-01	2018-11-01	美商艾伯維有限公司	穩定雙重可變區域免疫球蛋白蛋白質調配物
MX2015005593A (es)	2012-11-01	2016-02-05	Abbvie Inc	Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas.
JP6437441B2 (ja)	2012-11-02	2018-12-12	ティージーセラピューティクスインコーポレイテッド	抗ｃｄ２０抗体およびｐｉ３キナーゼ選択的阻害剤の組み合わせ
US9597380B2 (en)	2012-11-26	2017-03-21	Modernatx, Inc.	Terminally modified RNA
EP2934602B1 (en)	2012-12-19	2019-02-27	Genentech, Inc.	Methods and compositions for radiohalogen protein labeling
CA2896066C (en)	2012-12-21	2022-07-12	Biogen Ma Inc.	Human anti-tau antibodies
CA2896824A1 (en)	2012-12-31	2014-07-03	Neurimmune Holding Ag	Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
KR102391731B1 (ko)	2013-01-14	2022-04-27	젠코어 인코포레이티드	신규한 이형이량체 단백질
US9738722B2 (en)	2013-01-15	2017-08-22	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
US10309969B2 (en) *	2013-01-24	2019-06-04	Abtlas Co., Ltd.	Protein combination-based FV library, and preparation method therefor
WO2014124227A1 (en)	2013-02-07	2014-08-14	Immunomedics, Inc.	Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
FI3889173T3 (fi)	2013-02-15	2023-10-02	Bioverativ Therapeutics Inc	Optimoitu tekijä viii:n geeni
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP6444902B2 (ja)	2013-03-13	2018-12-26	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びその結合体
RU2019120404A (ru)	2013-03-13	2019-08-06	Дженентек, Инк.	Составы антител
AU2014244286B2 (en)	2013-03-14	2018-11-08	Duke University	Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
CA2904528C (en)	2013-03-15	2021-01-19	Abbvie Biotherapeutics Inc.	Fc variants
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
TWI745671B (zh)	2013-03-15	2021-11-11	美商百歐維拉提夫治療公司	因子ｉｘ多肽調配物
CN105324396A (zh)	2013-03-15	2016-02-10	艾伯维公司	针对IL-1β和/或IL-17的双重特异性结合蛋白
AU2014232416B2 (en)	2013-03-15	2017-09-28	Xencor, Inc.	Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
BR112015025347A2 (pt)	2013-04-09	2017-07-18	Boston Biomedical Inc	2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
HUE058364T2 (hu)	2013-04-19	2022-07-28	Cytune Pharma	Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
EP2805730A1 (en)	2013-05-21	2014-11-26	Bergen Teknologioverforing AS	Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2014190441A1 (en)	2013-05-31	2014-12-04	Zymeworks Inc.	Heteromultimers with reduced or silenced effector function
EP3013365B1 (en)	2013-06-26	2019-06-05	Academia Sinica	Rm2 antigens and use thereof
EP3013347B1 (en)	2013-06-27	2019-12-11	Academia Sinica	Glycan conjugates and use thereof
ES2658039T3 (es)	2013-07-10	2018-03-08	Sutro Biopharma, Inc.	Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2839842A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
EP3041484B1 (en)	2013-09-06	2021-03-03	Academia Sinica	Human inkt cell activation using glycolipids with altered glycosyl groups
IL312865B1 (en)	2013-09-11	2025-02-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-reducing agents
EP3052106A4 (en)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
EP3055298B1 (en)	2013-10-11	2020-04-29	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20160256460A1 (en)	2013-11-01	2016-09-08	Bergen Teknologioverføring As	Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
CA2963178C (en)	2013-11-12	2023-01-24	Ogd2 Pharma	Human igg1 derived antibody with pro-apoptotic activity
EP3083690A1 (en)	2013-12-17	2016-10-26	F.Hoffmann-La Roche Ag	Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
TW201620939A (zh)	2014-01-16	2016-06-16	中央研究院	治療及檢測癌症之組合物及方法
WO2015130416A1 (en)	2014-02-25	2015-09-03	Immunomedics, Inc.	Humanized rfb4 anti-cd22 antibody
EP2915569A1 (en)	2014-03-03	2015-09-09	Cytune Pharma	IL-15/IL-15Ralpha based conjugates purification method
TWI754319B (zh)	2014-03-19	2022-02-01	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
EP3129767B1 (en)	2014-03-27	2021-09-01	Academia Sinica	Reactive labelling compounds and uses thereof
ES2775431T3 (es)	2014-03-28	2020-07-27	Xencor Inc	Anticuerpos biespecíficos que se unen a CD38 y CD3
CN113046312A (zh)	2014-04-23	2021-06-29	朱诺治疗学股份有限公司	分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
EP3134113A4 (en)	2014-04-25	2017-11-29	University of Florida Research Foundation, Inc.	Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
KR102512592B1 (ko)	2014-05-27	2023-03-21	아카데미아 시니카	항-ｈｅｒ2 글리코항체 및 이의 용도
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7093612B2 (ja)	2014-05-27	2022-06-30	アカデミアシニカ	Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
KR20170003720A (ko)	2014-05-27	2017-01-09	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
KR102494193B1 (ko)	2014-05-28	2023-01-31	아카데미아 시니카	항-ｔｎｆ-알파 글리코항체 및 이의 용도
WO2015191969A1 (en)	2014-06-13	2015-12-17	Mayo Foundation For Medical Education And Research	Treating lymphomas
KR20170020371A (ko)	2014-06-16	2017-02-22	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	골수종의 치료
EP3160478A4 (en)	2014-06-30	2018-05-16	Bioverativ Therapeutics Inc.	Optimized factor ix gene
PL3166401T3 (pl)	2014-07-09	2021-01-25	F. Hoffmann-La Roche Ag	Dostosowanie pH w celu poprawy wyników regeneracji banków komórek po rozmrożeniu
EP4406549A3 (en)	2014-07-29	2025-01-08	Neurimmune Holding AG	Human-derived anti-huntingtin (htt) antibodies and uses thereof
EP3191500A4 (en)	2014-09-08	2018-04-11	Academia Sinica	HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
CN106687481B (zh)	2014-09-10	2022-03-22	豪夫迈·罗氏有限公司	半乳糖改造的免疫球蛋白1抗体
WO2016037644A1 (en)	2014-09-10	2016-03-17	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
SG11201701821QA (en)	2014-09-15	2017-04-27	Genentech Inc	Antibody formulations
US20160082120A1 (en)	2014-09-23	2016-03-24	Genentech, Inc.	METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
US10717778B2 (en)	2014-09-29	2020-07-21	Duke University	Bispecific molecules comprising an HIV-1 envelope targeting arm
AU2015326911B2 (en)	2014-09-30	2021-07-08	Neurimmune Holding Ag	Human-derived anti-dipeptide repeats (DPRs) antibody
MX2017004306A (es)	2014-10-01	2017-12-20	Eagle Biologics Inc	Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
SMT202000438T1 (it)	2014-11-17	2020-09-10	Regeneron Pharma	Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
MA55043A (fr)	2014-11-26	2021-12-29	Xencor Inc	Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
WO2016086196A2 (en)	2014-11-26	2016-06-02	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
WO2016105450A2 (en)	2014-12-22	2016-06-30	Xencor, Inc.	Trispecific antibodies
EP3242893A1 (en)	2015-01-08	2017-11-15	Biogen MA Inc.	Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
TWI736523B (zh)	2015-01-24	2021-08-21	中央研究院	新穎聚醣結合物及其使用方法
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
WO2016149485A1 (en)	2015-03-17	2016-09-22	The Regents Of The University Of California	Novel chemoimmunotherapy for epithelial cancer
CN115368460A (zh)	2015-03-17	2022-11-22	纪念斯隆-凯特林癌症中心	抗muc16抗体及其应用
EP4450524A2 (en)	2015-05-11	2024-10-23	F. Hoffmann-La Roche AG	Compositions and methods of treating lupus nephritis
SMT202000226T1 (it)	2015-05-30	2020-05-08	Molecular Templates Inc	Impalcatura di subunita' a della tossina shiga de-immunizzate e molecole di targeting cellulare comprendenti la stessa
TW201717935A (zh)	2015-06-03	2017-06-01	波士頓生醫公司	用於治療癌症的組成物和方法
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
BR112017024610A2 (pt)	2015-06-24	2018-07-31	F. Hoffmann-La Roche Ag	anticorpos para receptor antitransferrina com afinidade especificada
EP3108897A1 (en)	2015-06-24	2016-12-28	F. Hoffmann-La Roche AG	Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
AU2016285596A1 (en)	2015-06-29	2018-01-18	Genentech, Inc.	Type II anti-CD20 antibody for use in organ transplantation
CN108472337B (zh)	2015-08-03	2022-11-25	比奥贝拉蒂治疗公司	因子ix融合蛋白以及其制备和使用方法
PT3334747T (pt)	2015-08-13	2023-12-12	Amgen Inc	Formulação de gonadotrofina líquida estável
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
US11713358B2 (en)	2015-08-28	2023-08-01	Amunix Pharmaceuticals, Inc.	Chimeric polypeptide assembly and methods of making and using the same
US11352426B2 (en)	2015-09-21	2022-06-07	Aptevo Research And Development Llc	CD3 binding polypeptides
NZ741067A (en)	2015-10-02	2023-07-28	Hoffmann La Roche	Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
CN108473555B (zh)	2015-11-02	2022-10-25	生物蛋白有限公司	条件活性多肽
CN108699136B (zh)	2015-12-07	2022-03-18	Xencor股份有限公司	结合cd3和psma的异二聚抗体
KR20180098625A (ko)	2015-12-30	2018-09-04	제넨테크, 인크.	분해가 감소된 폴리소르베이트를 갖는 제형
EP3399861A4 (en)	2016-01-07	2019-08-07	Mayo Foundation for Medical Education and Research	METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
HRP20221089T1 (hr)	2016-02-01	2022-11-25	Bioverativ Therapeutics Inc.	Optimizirani geni faktora viii
AU2017217881B2 (en)	2016-02-12	2022-11-17	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
CN108699155B (zh)	2016-03-01	2023-03-21	豪夫迈·罗氏有限公司	具有改变的细胞死亡诱导的奥滨尤妥珠单抗变体
WO2017149018A1 (en)	2016-03-02	2017-09-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
CN109195996A (zh)	2016-03-08	2019-01-11	中央研究院	N-聚醣及其阵列的模组化合成方法
UA125378C2 (uk)	2016-03-14	2022-03-02	Універшітетет І Осло	МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn
JP7034489B2 (ja)	2016-03-15	2022-03-14	アイタブメッド（エイチケイ）リミテッド	多重特異性Ｆａｂ融合タンパクおよびその使用
WO2017165440A1 (en)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
CA3019373A1 (en)	2016-03-29	2017-10-05	Geltor, Inc.	Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
US10961311B2 (en)	2016-04-15	2021-03-30	Macrogenics, Inc.	B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2017182608A1 (en)	2016-04-22	2017-10-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and vaccine compositions for the treatment of b-cell malignancies
EA201892284A1 (ru)	2016-05-27	2019-08-30	Тг Терапьютикс, Инк.	Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
IL263542B2 (en)	2016-06-14	2024-10-01	Xencor Inc	Bispecific antibodies inhibit immunological checkpoint
WO2017218698A1 (en)	2016-06-15	2017-12-21	Sutro Biopharma, Inc.	Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
MX2018016265A (es)	2016-06-28	2019-07-04	Xencor Inc	Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3030745A1 (en)	2016-07-13	2018-01-18	Biogen Ma Inc.	Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
GB201613167D0 (en)	2016-07-29	2016-09-14	Univ Southampton	Cancer and b-cell related disease therapy
JP7213549B2 (ja)	2016-08-22	2023-01-27	シーエイチオーファーマインコーポレイテッド	抗体、結合性断片、および使用の方法
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN107384932B (zh)	2016-08-31	2020-10-20	北京天广实生物技术股份有限公司	抗人cd20人源化单克隆抗体mil62、其制备方法及用途
US11160876B2 (en)	2016-09-01	2021-11-02	Mayo Foundation For Medical Education And Research	Methods and compositions for targeting t-cell cancers
EP3506942B1 (en)	2016-09-01	2022-11-16	Mayo Foundation for Medical Education and Research	Carrier-pd-l1 binding agent compositions for treating cancers
US11590098B2 (en)	2016-09-06	2023-02-28	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3035655A1 (en)	2016-09-06	2018-03-15	Mayo Foundation For Medical Education And Research	Methods of treating pd-l1 expressing cancer
WO2018048958A1 (en)	2016-09-06	2018-03-15	Mayo Foundation For Medical Education And Research	Paclitaxel-albumin-binding agent compositions and methods for using and making the same
EP3509634A1 (en)	2016-09-09	2019-07-17	TG Therapeutics Inc.	Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
CN108421048B (zh) *	2016-09-28	2021-04-20	首都医科大学附属北京世纪坛医院	纳米活性碳靶向药物递送系统、制备方法及其用途
JP2019534882A (ja)	2016-10-11	2019-12-05	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	免疫介在性療法薬を有する抗体−薬物コンジュゲート
US10501543B2 (en)	2016-10-14	2019-12-10	Xencor, Inc.	IL15/IL15Rα heterodimeric Fc-fusion proteins
WO2018098376A1 (en)	2016-11-22	2018-05-31	Elektrofi, Inc.	Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
US11299469B2 (en)	2016-11-29	2022-04-12	Sumitomo Dainippon Pharma Oncology, Inc.	Naphthofuran derivatives, preparation, and methods of use thereof
WO2018100096A1 (en)	2016-12-01	2018-06-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
JP2020500874A (ja)	2016-12-02	2020-01-16	バイオベラティブセラピューティクスインコーポレイテッド	キメラ凝固因子を使用して血友病性関節症を処置する方法
CN110520149A (zh)	2016-12-02	2019-11-29	比奥维拉迪维治疗股份有限公司	诱导对凝血因子的免疫耐受性的方法
US20210238259A1 (en)	2017-01-31	2021-08-05	Bioverativ Therapeutics Inc.	Factor ix fusion proteins and methods of making and using same
GB201703876D0 (en)	2017-03-10	2017-04-26	Berlin-Chemie Ag	Pharmaceutical combinations
US10799597B2 (en)	2017-04-03	2020-10-13	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
SG11202003754YA (en)	2017-05-16	2020-05-28	Bhamis Research Laboratory Pvt Ltd	High concentration protein formulations with reduced viscosity
WO2018213424A1 (en)	2017-05-17	2018-11-22	Boston Biomedical, Inc.	Methods for treating cancer
CN111132733A (zh)	2017-06-30	2020-05-08	Xencor股份有限公司	含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
WO2019011918A1 (en)	2017-07-10	2019-01-17	International - Drug - Development - Biotech	TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
WO2019020606A1 (en)	2017-07-26	2019-01-31	F. Hoffmann-La Roche Ag	POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
US12168776B2 (en)	2017-08-09	2024-12-17	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof
US10759865B2 (en)	2017-08-22	2020-09-01	Eyal Levit	Treatment of diabetes mellitus
US11180541B2 (en)	2017-09-28	2021-11-23	Geltor, Inc.	Recombinant collagen and elastin molecules and uses thereof
WO2019077123A1 (en)	2017-10-20	2019-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en)	2017-11-08	2019-05-16	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-pd-1 sequences
SG11202005732XA (en)	2017-12-19	2020-07-29	Xencor Inc	Engineered il-2 fc fusion proteins
PL3765489T3 (pl)	2018-03-13	2025-02-10	F. Hoffmann-La Roche Ag	Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
EA202092316A1 (ru)	2018-03-28	2021-05-25	Бристол-Маерс Сквибб Компани	Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
WO2019195623A2 (en)	2018-04-04	2019-10-10	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
WO2019204665A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
GB2611498B (en)	2018-04-18	2023-07-19	Ucl Business Ltd	Composition comprising an engineered regulatory T cell (Treg)
EP3781598A1 (en)	2018-04-18	2021-02-24	Xencor, Inc.	Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019210054A1 (en)	2018-04-27	2019-10-31	Biogen Ma Inc.	Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody
KR20210016562A (ko)	2018-05-23	2021-02-16	에이디씨 테라퓨틱스 에스에이	분자 애쥬번트
BR112020025623A2 (pt)	2018-07-03	2021-03-23	Bristol-Myers Squibb Company	métodos de produção de proteínas recombinantes
CA3105947A1 (en)	2018-07-09	2020-01-16	Millennium Pharmaceuticals, Inc.	Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies
WO2020028909A1 (en)	2018-08-03	2020-02-06	Brown University	Oral formulations with increased uptake
CN109273050B (zh) *	2018-08-03	2021-07-13	五邑大学	一种用于解析复杂多聚体蛋白受体的脉冲电子顺磁共振数据的系统及方法与应用
US11590223B2 (en)	2018-08-31	2023-02-28	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
CN112955172A (zh)	2018-09-17	2021-06-11	美国卫生和人力服务部	靶向cd19和cd20的双顺反子嵌合抗原受体及其用途
KR20210069641A (ko)	2018-10-03	2021-06-11	젠코어 인코포레이티드	IL-12 이종이량체 Fc-융합 단백질
GB201816553D0 (en)	2018-10-10	2018-11-28	Centauri Therapeutics Ltd	Novel compounds and therapeutic uses thereof
GB201816554D0 (en)	2018-10-10	2018-11-28	Centauri Therapeutics Ltd	Novel compounds and therapeutic uses thereof
EP3864127A1 (en)	2018-10-10	2021-08-18	Boehringer Ingelheim International GmbH	Method for membrane gas transfer in high density bioreactor culture
EP3863672A4 (en)	2018-10-11	2022-06-29	The Scripps Research Institute	Antibody compounds with reactive arginine and related antibody drug conjugates
KR102262012B1 (ko)	2018-10-15	2021-06-09	연세대학교 산학협력단	생산성이 향상된 항체 및 이의 제조방법
RU2724469C2 (ru)	2018-10-31	2020-06-23	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с cd20
JP7453151B2 (ja)	2018-11-02	2024-03-19	協和キリン株式会社	液体培地の調製方法
CA3119467A1 (en)	2018-11-20	2020-05-28	Cornell University	Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
AU2018451747A1 (en)	2018-12-06	2021-06-17	F. Hoffmann-La Roche Ag	Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
WO2020115262A1 (en)	2018-12-07	2020-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
EP3917500A2 (en)	2019-01-31	2021-12-08	Elektrofi, Inc.	Particle formation and morphology
US11028176B2 (en)	2019-02-13	2021-06-08	The Brigham And Women's Hospital, Inc.	Anti-peripheral lymph node addressin antibodies and uses thereof
CN113728107B (zh)	2019-02-18	2022-06-24	Atb治疗公司	在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
BR112021016923A2 (pt)	2019-02-27	2021-11-03	Genentech Inc	Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
SG11202109406TA (en)	2019-03-01	2021-09-29	Xencor Inc	Heterodimeric antibodies that bind enpp3 and cd3
KR20210145152A (ko)	2019-04-01	2021-12-01	제넨테크, 인크.	단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
EP3953380A4 (en)	2019-04-12	2023-01-25	Geltor, Inc.	RECOMBINATION ELASTIN AND ASSOCIATED PRODUCTION
MX2021013825A (es)	2019-05-14	2022-01-18	Genentech Inc	Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
CN114269749B (zh)	2019-06-10	2024-10-01	苏特罗生物制药公司	5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
JP2022536800A (ja)	2019-06-17	2022-08-18	ストロバイオファーマインコーポレーテッド	Ｔｏｌｌ様受容体（ｔｌｒ）７／８アゴニストとしての１－（４－（アミノメチル）ベンジル）－２－ブチル－２ｈ－ピラゾロ［３，４－ｃ］キノリン－４－アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
JP2022543781A (ja)	2019-08-01	2022-10-14	ブリストル－マイヤーズスクイブカンパニー	フェッドバッチ細胞培養におけるタンパク質産生性の改良方法
CA3149049A1 (en)	2019-08-30	2021-03-04	Vestlandets Innovasjonsselskap As	Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
WO2021050645A1 (en)	2019-09-12	2021-03-18	Genentech, Inc.	Compositions and methods of treating lupus nephritis
CN114514035A (zh)	2019-09-13	2022-05-17	伊勒卓菲公司	递送用于治疗疾病的治疗性生物制剂的组合物和方法
EP4045090A1 (en)	2019-10-18	2022-08-24	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20230022576A1 (en)	2019-11-19	2023-01-26	Protalix Ltd.	Removal of constructs from transformed cells
IL295202A (en)	2020-01-31	2022-10-01	Seagen Inc	Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
US20230065628A1 (en)	2020-02-19	2023-03-02	Elektrofi, Inc.	Droplet Formation and Particle Morphology
EP4114852A1 (en)	2020-03-03	2023-01-11	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
JP2023522627A (ja)	2020-04-17	2023-05-31	エレクトロフィ，インコーポレイテッド	連続的な液滴形成及び脱水によって粒子を形成する方法
AU2021259861A1 (en)	2020-04-24	2022-11-17	Genentech, Inc.	Methods of using anti-CD79b immunoconjugates
IL297545A (en)	2020-04-26	2022-12-01	Biocytogen Pharmaceuticals Beijing Co Ltd	Modified immunoglobulins
WO2021223048A1 (zh)	2020-05-03	2021-11-11	上海美雅珂生物技术有限责任公司	抗体药物偶联物及其制剂
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
GB202007842D0 (en)	2020-05-26	2020-07-08	Quell Therapeutics Ltd	Polypeptide useful in adoptive cell therapy
JP2023537565A (ja)	2020-06-24	2023-09-04	バイオベラティブセラピューティクスインコーポレイテッド	タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
JP2023536602A (ja)	2020-08-03	2023-08-28	ジェネンテック，インコーポレイテッド	リンパ腫のための診断及び治療方法
GB202012331D0 (en)	2020-08-07	2020-09-23	Petmedix Ltd	Therapeutic antibodies
US11919958B2 (en)	2020-08-19	2024-03-05	Xencor, Inc.	Anti-CD28 compositions
CN112062855B (zh)	2020-08-26	2024-08-30	北京天诺健成医药科技有限公司	一种含有衔接器的药物治疗剂的开发和应用
WO2022043415A1 (en)	2020-08-27	2022-03-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for detecting the presence of pemphigus-specific autoantibodies in a sample
GB202013477D0 (en)	2020-08-27	2020-10-14	Quell Therapeutics Ltd	Nucleic acid constructs for expressing polypeptides in cells
KR20230066581A (ko)	2020-09-10	2023-05-16	젠맵 에이/에스	미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
WO2022053653A1 (en)	2020-09-10	2022-03-17	Genmab A/S	Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
US20240034812A1 (en)	2020-09-10	2024-02-01	Genmab A/S	Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116507363A (zh)	2020-09-10	2023-07-28	健玛保	用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
AU2021341509A1 (en)	2020-09-10	2023-04-13	Genmab A/S	Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
KR20230073270A (ko)	2020-09-22	2023-05-25	브리스톨-마이어스 스큅 컴퍼니	치료 단백질의 생산 방법
WO2022074646A1 (en)	2020-10-05	2022-04-14	Protalix Ltd.	Dicer-like knock-out plant cells
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
WO2022103983A2 (en)	2020-11-11	2022-05-19	Sutro Biopharma, Inc.	Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
WO2022104150A1 (en)	2020-11-12	2022-05-19	Tg Therapeutics, Inc.	Triple combination to treat b-cell malignancies
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
CA3212665A1 (en)	2021-03-09	2022-09-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko)	2021-03-10	2023-11-07	젠코어 인코포레이티드	Cd3 및 gpc3에 결합하는 이종이량체 항체
IL305283A (en)	2021-03-15	2023-10-01	Genentech Inc	Compositions and methods of treating lupus nephritis
CN117529505A (zh)	2021-03-24	2024-02-06	美国卫生和人力服务部	设计为减少逆转录病毒重组的双顺反子嵌合抗原受体及其用途
TW202306983A (zh)	2021-04-20	2023-02-16	日商日本醫事物理股份有限公司	抗ｃｄ２０抗體之放射性複合體，及放射性醫藥
EP4334354A1 (en)	2021-05-06	2024-03-13	Dana-Farber Cancer Institute, Inc.	Antibodies against alk and methods of use thereof
CA3218170A1 (en)	2021-05-12	2022-11-17	Jamie Harue HIRATA	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20240270862A1 (en)	2021-06-01	2024-08-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of b cell depleting agents for the treatment of rheumatic heart disease
CN117412988A (zh)	2021-06-08	2024-01-16	修普霍斯生物科学有限公司	抗体-nkg2d配体结构域融合蛋白
BR112023025884A2 (pt)	2021-06-08	2024-02-27	Xyphos Biosciences Inc	Proteína de fusão de domínio de ligante de anticorpo de nkg2d
CN117580862A (zh)	2021-06-17	2024-02-20	葛兰素史克知识产权有限公司	用于治疗长新冠和/或SARS-CoV-2感染后急性后遗症(PASC)的方法的抗BAFF抗体
JP2024526122A (ja)	2021-06-17	2024-07-17	ペットメディックス・リミテッド	抗イヌｃｄ２０抗体
EP4377338A2 (en)	2021-07-27	2024-06-05	Novab, Inc.	Engineered vlrb antibodies with immune effector functions
WO2023015234A1 (en)	2021-08-05	2023-02-09	Bristol-Myers Squibb Company	Cell culture methods for producing therapeutic proteins
WO2023012486A1 (en)	2021-08-06	2023-02-09	Petmedix Ltd	Antibody fc variants
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
TW202323274A (zh)	2021-08-23	2023-06-16	美商百歐維拉提夫治療公司	優化因子viii基因
IL310963A (en)	2021-08-23	2024-04-01	Bioverativ Therapeutics Inc	Production of closed DNA with inverted repeat sequences
WO2023049687A1 (en)	2021-09-21	2023-03-30	Bristol-Myers Squibb Company	Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
TW202346327A (zh)	2021-09-30	2023-12-01	美商百歐維拉提夫治療公司	編碼具有降低免疫原性的因子ｖｉｉｉ多肽之核酸
WO2023097024A1 (en)	2021-11-24	2023-06-01	Dana-Farber Cancer Institute, Inc.	Antibodies against ctla-4 and methods of use thereof
US20250051472A1 (en)	2021-12-17	2025-02-13	Dana-Farber Cancer Institute, Inc.	Antibodies and uses thereof
CA3241407A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
US20230303693A1 (en)	2022-01-28	2023-09-28	Genmab A/S	Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
EP4472670A1 (en)	2022-02-04	2024-12-11	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treatment of neurological disorders
WO2023152486A1 (en)	2022-02-09	2023-08-17	Petmedix Ltd	Therapeutic antibodies
WO2023164487A1 (en)	2022-02-22	2023-08-31	Brown University	Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
EP4508080A1 (en)	2022-04-11	2025-02-19	Astrazeneca AB	T cell binding proteins
CN119403542A (zh)	2022-04-29	2025-02-07	伊勒卓菲公司	可注射悬浮液
US11807689B1 (en)	2022-06-01	2023-11-07	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11814439B1 (en)	2022-06-01	2023-11-14	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11965032B1 (en)	2022-06-01	2024-04-23	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11884740B1 (en)	2022-06-01	2024-01-30	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
IL316919A (en)	2022-06-27	2025-01-01	Sutro Biopharma Inc	Β-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
WO2024015229A1 (en)	2022-07-15	2024-01-18	Sutro Biopharma, Inc.	Protease/enzyme cleavable linker-payloads and protein conjugates
WO2024039670A1 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against msln and methods of use thereof
WO2024102734A1 (en)	2022-11-08	2024-05-16	Genentech, Inc.	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024153636A1 (en)	2023-01-17	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Vasorin as a biomarker and biotarget in nephrology
WO2024182516A1 (en)	2023-02-28	2024-09-06	Juno Therapeutics, Inc.	Cell therapy for treating systemic autoimmune diseases
WO2024254455A1 (en)	2023-06-08	2024-12-12	Genentech, Inc.	Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025021782A1 (en)	2023-07-24	2025-01-30	Institut National de la Santé et de la Recherche Médicale	Methods of determining whether a subject suffering from lupus nephritis (ln) will achieve a response with an induction therapy
WO2025029832A2 (en)	2023-07-31	2025-02-06	Sutro Biopharma, Inc.	Sting agonist compounds and conjugates

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US26804A (en) *		1860-01-10		Bridle-bit
US21781A (en) *		1858-10-12		Improved method o f lighting street-lamps by electricity
US213784A (en) *		1879-04-01		Improvement in inlaying metallic scroll-ornaments in hard rubber and allied gums
US186205A (en) *		1877-01-16		Improvement in buffing-rolls for thesoles of boots andshoes
US147885A (en) *		1874-02-24		Improvement in the manufacture of halters and bridles
US9444A (en) *		1852-12-07		Hot-air furnace
US197255A (en) *		1877-11-20		Improvement in receivers and stench-traps for street-sewers
US206903A (en) *		1878-08-13		Improvement in cultivators
US95963A (en) *		1869-10-19		Improvement in fence
US163708A (en) *		1875-05-25		Improvement in harvester-rakes
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0173494A3 (en) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
USRE38008E1 (en) *	1986-10-09	2003-02-25	Neorx Corporation	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6893625B1 (en) *	1986-10-27	2005-05-17	Royalty Pharma Finance Trust	Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) *	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) *	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5439665A (en) *	1988-07-29	1995-08-08	Immunomedics	Detection and treatment of infectious and inflammatory lesions
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH06501705A (ja) *	1990-11-05	1994-02-24	ブリストル−マイアーズ　スクイブ　カンパニー	抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
IE922437A1 (en) *	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
US5686072A (en) *	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
NZ258392A (en) *	1992-11-13	1997-09-22	Idec Pharma Corp	Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5678180A (en) *	1995-06-07	1997-10-14	Hughes Electronics	Communication system and method providing dispatch and cellular interconnect communications
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) *	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies

1993
- 1993-11-03 US US08/149,099 patent/US5736137A/en not_active Expired - Lifetime
- 1993-11-12 DE DE69334285T patent/DE69334285D1/de not_active Expired - Lifetime
- 1993-11-12 UA UA95062664A patent/UA27946C2/uk unknown
- 1993-11-12 CN CN2004100488083A patent/CN1607006B/zh not_active Expired - Lifetime
- 1993-11-12 HU HU9501410A patent/HU219264B/hu active Protection Beyond IP Right Term
- 1993-11-12 CN CN2006100900829A patent/CN1912111B/zh not_active Expired - Lifetime
- 1993-11-12 PT PT99123967T patent/PT1005870E/pt unknown
- 1993-11-12 PT PT08013898T patent/PT2000149E/pt unknown
- 1993-11-12 AT AT99123967T patent/ATE421335T1/de active
- 1993-11-12 CN CN2006100900848A patent/CN101007851B/zh not_active Expired - Lifetime
- 1993-11-12 IL IL10759193A patent/IL107591A/xx not_active IP Right Cessation
- 1993-11-12 AT AT08013898T patent/ATE431158T1/de active
- 1993-11-12 DK DK99123967T patent/DK1005870T3/da active
- 1993-11-12 SG SG1996002951A patent/SG45294A1/en unknown
- 1993-11-12 ZA ZA938466A patent/ZA938466B/xx unknown
- 1993-11-12 MY MYPI93002374A patent/MY111196A/en unknown
- 1993-11-12 EP EP08013898A patent/EP2000149B1/en not_active Expired - Lifetime
- 1993-11-12 KR KR1019950701928A patent/KR100365632B1/ko not_active IP Right Cessation
- 1993-11-12 CN CN200610090080XA patent/CN101007850B/zh not_active Expired - Lifetime
- 1993-11-12 PL PL93320526A patent/PL175557B1/pl unknown
- 1993-11-12 ES ES08013898T patent/ES2326144T3/es not_active Expired - Lifetime
- 1993-11-12 DK DK08013898T patent/DK2000149T3/da active
- 1993-11-12 DE DE122009000070C patent/DE122009000070I1/de active Pending
- 1993-11-12 CN CNB931214246A patent/CN1270774C/zh not_active Expired - Lifetime
- 1993-11-12 ES ES99123967T patent/ES2321567T3/es not_active Expired - Lifetime
- 1993-11-12 DE DE69334259T patent/DE69334259D1/de not_active Expired - Lifetime
- 1993-11-12 CA CA002626445A patent/CA2626445A1/en not_active Withdrawn
- 1993-12-14 TW TW082110578A patent/TW376320B/zh not_active IP Right Cessation
1997
- 1997-05-13 BR BR1100622-6A patent/BR1100622A/pt active IP Right Grant
2002
- 2002-03-14 US US10/096,964 patent/US20030082172A1/en not_active Abandoned
2004
- 2004-07-15 FR FR04C0018C patent/FR04C0018I2/fr active Active
2006
- 2006-07-07 GE GEAP20069498A patent/GEP20074162B/en unknown
2008
- 2008-01-11 HK HK08100410.4A patent/HK1109634A1/xx not_active IP Right Cessation
- 2008-01-11 HK HK08100409.7A patent/HK1109633A1/xx not_active IP Right Cessation
2009
- 2009-05-13 HK HK09104369.6A patent/HK1125574A1/xx not_active IP Right Cessation
- 2009-11-10 NL NL300424C patent/NL300424I1/nl unknown
- 2009-11-11 LU LU91620C patent/LU91620I2/fr unknown
2010
- 2010-01-06 GE GEAP200911620A patent/GEPI20105119B/en unknown
- 2010-01-06 GE GEAP201011620A patent/GEP20105119B/en unknown

Also Published As

Publication number	Publication date
HU9501410D0 (en)	1995-06-28
SG45294A1 (en)	1998-01-16
ATE421335T1 (de)	2009-02-15
CN101007850B (zh)	2012-05-30
FR04C0018I2 (pt)	2009-11-20
TW376320B (en)	1999-12-11
CN101007851B (zh)	2012-09-12
DK2000149T3 (da)	2009-08-03
HK1109634A1 (en)	2008-06-13
GEPI20105119B (en)	2010-11-25
DE69334259D1 (de)	2009-03-12
NL300424I1 (nl)	2010-01-04
LU91620I2 (fr)	2010-01-11
ES2321567T3 (es)	2009-06-08
ZA938466B (en)	1994-06-20
CN1270774C (zh)	2006-08-23
CN101007851A (zh)	2007-08-01
GEP20074162B (en)	2007-07-10
CN1912111B (zh)	2010-05-26
KR100365632B1 (ko)	2003-08-02
GEP20105119B (en)	2010-11-25
BR1100622A (pt)	2000-04-18
HK1109633A1 (en)	2008-06-13
HU219264B (en)	2001-03-28
CN101007850A (zh)	2007-08-01
EP2000149A1 (en)	2008-12-10
DE69334285D1 (de)	2009-06-25
CN1912111A (zh)	2007-02-14
DK1005870T3 (da)	2009-05-18
US5736137A (en)	1998-04-07
ATE431158T1 (de)	2009-05-15
CN1607006A (zh)	2005-04-20
FR04C0018I1 (pt)	2008-09-26
IL107591A0 (en)	1994-02-27
EP2000149B1 (en)	2009-05-13
ES2326144T3 (es)	2009-10-01
CN1607006B (zh)	2012-09-19
PL175557B1 (pl)	1999-01-29
MY111196A (en)	1999-09-30
US20030082172A1 (en)	2003-05-01
HUT72914A (en)	1996-06-28
HK1125574A1 (en)	2009-08-14
UA27946C2 (uk)	2000-10-16
PT2000149E (pt)	2009-07-14
IL107591A (en)	2000-02-17
CN1094965A (zh)	1994-11-16
DE122009000070I1 (de)	2010-02-11
CA2626445A1 (en)	1994-05-26